---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331381"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-08-04T10:01:39+00:00"
generated_at: "2026-08-04T10:10:37.426780+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEAYA: darovasertib combo meets primary endpoint in mUM; Q2 net loss $112.5M; cash $1.24B

## Summary
- Registrational OptimUM-02 trial met primary endpoint: median PFS 6.9 vs 3.1 months (HR 0.42, p<0.0001); NDA filing underway under RTOR.
- Q2 2026 net loss $112.5M vs $98.5M in Q1; R&D expenses $108.7M; G&A $22.5M.
- Cash, cash equivalents and marketable securities $1.24B as of June 30, 2026; cash runway into 2030 unchanged.
- Clinical collaboration with Roche to evaluate IDE892 + RG6505 in MTAP-deleted, RAS-mutant PDAC; Phase 1 combo trial to start H2 2026.
- Updated data from IDE849 (DLL3 ADC) and OptimUM-01/09 at ESMO; Phase 3 registrational trial for IDE849 targeted by end 2026.

## SEC filing metadata
- accession: 0001193125-26-331381
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-08-04T10:01:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/0001193125-26-331381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331381
- JSON: https://secwatch.observer/filing/0001193125-26-331381.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.